Back to Journals » Vascular Health and Risk Management » Volume 13

Original Research

Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy

         
Total article views   Abstract views HTML views PDF downloads Totals
5,308 Dovepress* 3,915 647+ 1,375 4,562
PubMed Central* 0 746 235 746
Totals 3,915 1,393 1,610 5,308
*Since 6 July 2017
+Since July 2016

View citations on PubMed Central and Google Scholar